Harvard Medical School Study Validates Opportunity for Urigen Pharmaceuticals, Inc.’s Platform Technology To Develop Treatment for Painful Bladder Syndrome

SAN FRANCISCO--(BUSINESS WIRE)--Urigen Pharmaceuticals, Inc. (OTC BB: URGP), a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that a recent epidemiological study conducted by researchers at the Harvard Medical School has demonstrated that Painful Bladder Syndrome (PBS) is a commonly occurring disorder amongst women, further supporting the Company’s focus on developing treatments for the condition.